rVSV-∆G-spike
A candidate COVID-19 vaccine.
General information
rVSV-∆G-spike is a replication competent recombinant candidate vaccine derived from vesicular stomatitis virus with glycoprotein exchanged for SARS-CoV-2 Spike protein (Yahalom-Ronen et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
Viral vector Animal model In vitro Mixed substance |
Vero E6 cells; C57BL/6J mice; golden Syrian hamsters | 12.12 | The vaccine was neutralised by human convalescent COVID-19 serum in vitro. Intramuscular administration of the vaccine was safe in a Syrian hamster model. The vaccination elicited dose-dependent neutralizing antibody response and it protected the experimental animals in a viral challenge (the vaccinated hamsters showed only a mild and temporary weight loss, it prevented lung tissue damage associated with SARS-CoV-2 infection, and the hamsters' lung viral loads on day 5 post challenge were below the detection limit). In mice, the vaccination resulted in high titres of anti-S protein and neutralising antibodies. |
Dec/16/2020 |
